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The RET proto-oncogene encodes a protein structurally related to transmembrane receptors with an intracellular tyrosine
kinase domain. In human thyroid gland, the RET proto-oncogene is normally expressed in parafollicular C-cells. Thyroid C-cell
hyperplasia is associated with inherited medullary thyroid carcinomas and is considered as a pre-neoplastic stage of C-cells
disease. It has also been observed in thyroid tissues adjacent to follicular and papillary carcinomas. In order to study the
relationship between a misfunctioning of the RET proto-oncogene and the presence of C-cell hyperplasia, we compared a
series of thyroid glands presenting sporadic or radiation-associated tumours, as well as samples of unrelated normal thyroid
tissues, for alteration in exons 10 and 11 of the gene and for the presence or absence of C-cell hyperplasia. Here we report a
signiﬁcantly higher frequency of C-cell hyperplasia present in peritumoural thyroid tissues of radiation-induced epithelial thyroid
tumours, than in peritumoural of sporadic thyroid tumours or in control normal thyroid tissues (P=0.001). A G691S RET
polymorphism was present with a higher frequency in radiation-induced epithelial thyroid tumours (55%) than in sporadic
tumours (20%) and in control normal thyroid tissues (15%). Interestingly, this polymorphism was associated in the majority
(88%) of radiation-induced tumours with a C-cell hyperplasia in the peritumoural tissues. Several explanations for this
association are discussed.
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Since 1950, when the ﬁrst epidemiological study relating external
beam radiation exposure and thyroid cancer was published (Duffy
and Fitzgerald, 1950), an increased incidence of this type of
tumour has been observed in populations including atomic bomb
survivors (Thompson et al, 1994), inhabitants of regions affected
by a thermonuclear test (Conard, 1984) and patients with a history
of external radiation for benign or malignant conditions (Shore,
1992). Radiation-associated thyroid tumours were also observed
in children contaminated in Ukraine and Belarus as a consequence
of the Chernobyl accident (Kazakov et al, 1992).
Radiation-associated thyroid tumours are the most frequent
radiation-induced tumours in man and the increase in the relative
risk of developing a thyroid tumour following a radiation dose of
1 Gy to the gland during childhood, is equal to 7.7 (Ron et al,
1995). Studies concerning the research of genetic alterations in
radiation-induced epithelial thyroid tumours, have concerned the
RAS, GSP, RET, TRK, and P53 genes (for review Suarez, 1998).
These data showed a crucial role for RET activating rearrangements
in the initiation and/or the development of the radiation-associated
epithelial thyroid tumourigenic process (Suarez, 1998).
The RET proto-oncogene located on chromosome 10q11.2
encodes a protein structurally related to transmembrane receptors
with an intracellular tyrosine kinase domain (Takahashi et al,
1985; Takahashi and Cooper, 1987). The ligands for RET have been
recently identiﬁed as neurotrophic factors of the glial-cell-line
derived neurotrophic factor (GDNF) family, including GDNF,
neurturin, artemin, and perseptin (reviewed in Airaksinen et al,
1999; Baloh et al, 2000). The gene is expressed in a variety of
neuronal cell lineages as well as in the kidney and enteric nervous
system (Pachnis et al, 1993). In the normal human thyroid gland,
the RET proto-oncogene is normally expressed in parafollicular C-
cells, suggesting its involvement in the growth regulation of these
cells (Fabien et al, 1994). The identiﬁcation of germline point
mutations in different domains of the RET proto-oncogene in
inherited human diseases, namely Multiple Endocrine Neoplasia
type 2A and 2B (MEN2A and MEN2B), familial or sporadic
medullary thyroid carcinoma (MTC) and Hirschsprung’s disease
(Donis-Keller et al, 1993; Mulligan et al, 1993; Edery et al, 1994;
Hofstra et al, 1994; for review Eng, 1999), conﬁrms that this gene
plays a critical role in the differentiation and growth of speciﬁc cell
lineages of neural crest origin (i.e. thyroid C-cells).
Thyroid C-cell hyperplasia (CCH) was ﬁrst described in the
early 1970’s as a lesion associated with familial MTC and MEN
2A and 2B (Wolfe et al, 1973; DeLellis and Wolfe, 1981; LiVolsi,
1997), and is considered as a pre-neoplastic stage of C-cell disease.
CCH was also found to be associated with several other conditions.
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www.bjcancer.comIn fact, CCH was recognised in some patients with Hashimoto
thyroiditis (Libbey et al, 1989) as well as in some other patients
with chronic lymphocytic thyroiditis not within the context of
MTC or MEN (Guyetant et al, 1994). In addition, CCH was also
observed for the ﬁrst time by Albores-Saavedra et al (1988), in
thyroid tissue adjacent to follicular and papillary neoplasms.
In order to look for an eventual relationship between the
presence of C-cell hyperplasia in normal thyroid tissues surround-
ing epithelial thyroid tumours and a possible misfunctioning of the
RET proto-oncogene, we analysed a series of thyroid glands
presenting sporadic or radiation-associated tumours as well as
samples of unrelated normal thyroid tissue.
MATERIALS AND METHODS
Tumoural thyroid tissues were collected at the Gustave Roussy
Institute (Villejuif, France) and were histologically classiﬁed
according to the WHO classiﬁcation (Hedinger et al, 1988).
Normal unrelated thyroid tissues were collected at the Hospital
de Clinicas of Buenos Aires (Argentina) by Dr J Garcia. A total
of 29 thyroid tumours obtained from patients with a history of
external irradiation for benign or malignant conditions were exam-
ined: 14 follicular adenomas, 11 papillary carcinomas (PTC) and 4
widely invasive follicular carcinomas (WIFC) (Table 1). As controls
we studied 29 human thyroid tumours collected from patients
without any history of radiation (15 follicular adenomas, 12 PTC
and 2 WIFC) (Table 2) and 20 samples of unrelated normal thyr-
oid tissue.
The presence of a C-cell hyperplasia (CCH) was investigated in
parafﬁn embedded tissue sections, using an immunohistochemical
technique previously described (Guyetant et al, 1999). The
calcitonin polyclonal antibody used was from DAKO (A576). The
test was performed with a streptavidin-Biotin-Peroxydase kit
(LSAB-Dako-K675), after treatment with diaminobenzidine. The
nuclei were stained with Mayer’s Haematoxylin. The slides showing
a CCH in thyroid tissue adjacent to follicular cell radio-induced
tumours were carefully examined. One example of CCH in peri-
tumoural tissue of a patient with a radiation-induced thyroid
tumour is shown in Figure 1. A C-cell hyperplasia diagnosis was
made when at least three low-power ﬁelds (6100 magniﬁcation)
containing more than 50 calcitonin-immunostained C-cells were
observed (Guyetant et al, 1994).
Genomic DNA was extracted from frozen and/or parafﬁn
embedded thyroid tissue samples, as described by Suarez et al
(1990, 1991). Ampliﬁcation of exons 10 and 11 of RET gene,
was carried out with 250 ng genomic DNA, 250 nmol of each
primer, 200 nmol dNTPs, Taq polymerase buffer (Perkin Elmer),
1.5 mmol MgCl2 and 2 U Taq DNA polymerase (Perkin Elmer
Cetus). The following temperature cycling conditions were used:
one cycle 3 min at 948C and 2 min at 688C (exon 10) or 608C
(exon 11), followed by 35 cycles of 30 s at 948C, 30 s at 688C (exon
10) or 608C (exon 11) and 1 min at 728C. At the end of the 35
cycles, the PCR products were extended for 10 min at 728C. Two
pairs of primers were used to amplify exons 10 and 11 of the
RET gene. These primers were: exon 10: (sense) 5'-gcgccccaggaggct-
gagtg-3' and (anti-sense) 5'-cgtggtggtcccggccgcc-3'; exon11: (sense)
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Table 1 Association of RET codon 691 (GGT?AGT:gly?ser) polymorphism in radiation-induced thyroid tumours with
C-cell hyperplasia in peritumoural tissue
Age at
irradiation (year)
Sex and Age at
tumour diagnosis
Presence of C-cell
hyperplasia in
BanI digestion products
Sample and dose (Gy)
a (year) Histology
b peritumoural tissue Tumour Lymphocyte
Ti85
c 2/0.1 F/5 PTC + A1/A2
d
Ti101 36/10 F/47 PTC 7 A1 A1
Ti228 5/7.3 F/25 PTC 7 A1
Ti230
c 3/nd F/38 PTC + A2 A1/A2
Ti231 1/4.5 F/20 PTC 7 A1
Ti236 24/14 M/34 PTC 7 A1 A1
Ti247
c 5/nd F/24 PTC + A2 A1/A2
Ti248
c 2/nd F/22 PTC + A1/A2
Ti249
c 1/0.24 M/23 PTC + A2 A1/A2
Ti250 9/9 M/28 PTC 7 A1
Ti251
c 13/nd F/28 PTC 7 A1/A2
Ti31
c 12/nd F/42 Macr. Ad. + A2
Ti216 44/nd F/58 Macr. Ad. 7 A1
Ti238 25/nd M/53 Macr. Ad. 7 A1 A1
Ti271 6/14 M/21 Macr. Ad. + A1
Ti225 12/10.5 F/38 Mix. Ad. 7 A1 A1
Ti234
c 4/15.5 F/18 Mix. Ad. + A2 A1/A2
Ti274 1/0.18 F/27 Mix. Ad. + A1
Ti121 26/12 F/46 Micr. Ad. 7 A1 A1
Ti154
c 1/0.2 F/33 Micr. Ad. + A2
Ti226
c 13/13 M/34 Micr. Ad. + A2 A1/A2
Ti232
c 4/29.2 M/21 Micr. Ad. + A2
Ti239
c 2/nd F/22 Micr. Ad. + A2 A1/A2
Ti252
c 1/10 M/27 Micr. Ad. 7 A1/A2
Ti270
c 3/13 M/20 Micr. Ad. + A2
Ti88 8/nd F/45 WIFC 7 A1
Ti155 23/nd M/33 WIFC 7 A1
Ti233 1/nd F/6 WIFC + A2 A2
Ti255 14/nd M/27 WIFC + A2
aDose received by the thyroid gland calculated according to Diallo et al (1996);
bMacr. Ad.=macrofollicular adenoma; Mix. Ad.=mixed
adenoma (macro and microfollicular regions); Micr. Ad.=microfollicular adenoma; PTC=papillary thyroid carcinoma; WIFC=widely inva-
sive follicular carcinoma.
cTumours positive for RET/PTC1 or RET/PTC3 (Bounacer et al, 1997).
dA1 is always deﬁned as the wild type allele
with the restriction site present, A2 with the restriction site absent.
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gcc-3'.
Direct sequence analysis of the ampliﬁed DNA fragments was
carried out by the dideoxy-nucleotide method with [g
33P] ATP,
using the double strand DNA cycle sequencing system kit (BRL,
Life Technologies) and the same primers as those employed for
the ampliﬁcation, following the manufacturer’s conditions. The
reaction mixtures were then resolved on standard 8% acrylamide
sequencing gels. Following electrophoresis, gels were dried and
autoradiographed with X-ray ﬁlm overnight.
To look for the presence of an eventual polymorphism in codon
691 RET (see below) by restriction enzyme digestion, 20 ml of puri-
ﬁed exon 11 ampliﬁcation product, was digested with 20 U of BanI
(Biolabs) at 378C all overnight for a complete digestion. After incu-
bation the samples were separated by electrophoresis in a 2%
agarose gel (see Figure 3). Indeed, when a GGT?AGT sequence
variant at codon 691 is present, there is loss of a BanI restriction
site and only one fragment of 408 bp (mutated allele A2) is
detected instead of normally two fragments of 185 and 223 bp
(wild type allele A1).
Statistical analysis was made using the Chi-square test to deter-
mine whether the associations between radiation-induced thyroid
tumours with follicular phenotypes and CCH; and between
G691S RET sequence variant and CCH, were signiﬁcant.
RESULTS
The population of patients receiving therapeutic radiation in
infancy consisted of 29 subjects (18 women, 11 men; sex ratio F/
M: 1.63), ranging in age at diagnosis from 5 to 58 years, with a
mean age of 29.8 years. Only two patients were over 50 years of
age (Table 1). The immunohistochemical study showed that 16
patients (55%), 10 women and 6 men, had C-cell hyperplasia
(CCH) in the non-neoplastic peritumoural thyroid tissue. The
tumours of these 16 irradiated patients were classiﬁed as follicular
adenoma (Ad) in nine of 14 (64%), papillary carcinoma (PTC) in
ﬁve of 11 (45%), and widely invasive follicular carcinoma (WIFC)
in two of 4 (50%) (Table 1). As control, a total of 29 sporadic
thyroid tumours obtained from patients without any history of
radiation (sex ratio F/M: 2.6; average age at diagnosis: 40.4 years)
and 20 unrelated normal thyroid tissues were screened for CCH.
The C-cell hyperplasia was present in just 7% (2/29) of the thyroid
glands presenting a sporadic tumour (1/15 Ad: 6.7%, 1/12 PTC:
8.4%, and 0/2 WIFC) (Table 2), and 10% (2/20) of the unrelated
normal thyroid tissues (data not shown).
The C-cell hyperplasia was observed in normal tissue surround-
ing tumours from all patients who had received external radiation
before the age of 15, with an average of 4.6 years (16/16; Table 1).
There was no relationship between the dose of radiation to the
thyroid and the presence of CCH (Table 1). One example of
CCH, as deﬁned in Materials and Methods, in peritumoural tissue
of a patient with a radiation-induced thyroid tumour is shown in
Figure 1. As expected, all thyroid tumours, adenomas, follicular
carcinomas, and papillary carcinomas were calcitonin negative.
We looked then for the eventual presence of RET genetic altera-
tions in our radiation-associated and sporadic tumours as well as
in samples of unrelated normal thyroid tissue. We began our study
investigating the presence or absence of point mutations in exons
10 and 11 of the gene. After PCR the ampliﬁed DNAs were directly
sequenced. No mutations were detected in exon 10. However, a
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Table 2 RET polymorphism in codon 691 (GGT?AGT:gly?ser) and C-cell hyperplasia in thyroid
glands with sporadic tumours
Sample
Sex and age
at tumour diagnosis
(year) Histology
a
Presence of C-cell
hyperplasia in
peritumoural tissue BanI digestion products
c
Ti8 F/37 PTC 7 A1
Ti18 F/15 PTC 7 A1
Ti19 M/22 PTC 7 A1
Ti24 F/30 PTC 7 A1
Ti33 M/39 PTC 7 A1/A2
Ti38 M/56 PTC 7 A1/A2
Ti40
b F/32 PTC + A2
Ti43 F/46 PTC 7 A1
Ti48 F/39 PTC 7 A1
Ti102 M/55 PTC 7 A1
Ti122 M/36 PTC 7 A1
Ti125 F/63 PTC 7 A1
Ti16 F/26 Mac. Ad. 7 A1/A2
Ti27 F/22 Mac. Ad. 7 A1
Ti37 F/29 Mac. Ad. 7 A1
Ti56 F/35 Mac. Ad. + A1
Ti66 M/61 Mac. Ad. 7 A1
Ti120 F/64 Mac. Ad. 7 A1
Ti12 F/41 Mix. Ad. 7 A1
Ti23 F/58 Mix. Ad. 7 A1
Ti39 F/46 Mix. Ad. 7 A1
Ti60 F/42 Mix. Ad. 7 A1
Ti119 M/69 Mix. Ad. 7 A1
Ti28 F/12 Micr. Ad. 7 A1/A2
Ti29 F/28 Micr. Ad. 7 A1/A2
Ti32 F/43 Micr. Ad. 7 A1
Ti41 F/43 Micr. Ad. 7 A1
Ti15 M/57 WIFC 7 A1
Ti16 F/26 WIFC 7 A1
aMacr. Ad.=macrofollicular adenoma; Mix. Ad.=mixed adenoma (macro and microfollicular regions); Micr.
Ad.=microfollicular adenoma; PTC=papillary thyroid carcinoma; WIFC=widely invasive follicular carcinoma.
bTi40
was positive for RET/PTC1 (Bounacer et al, 1997).
cA1: wildtype allele; A2: mutated allele.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1929–1936sequence variant in codon 691 of exon 11, changing a G to an A
(GGT?AGT: gly?ser) and giving rise to a single nucleotide poly-
morphism (SNP) already described in the literature (Bugalho et al,
1994, Ceccherini et al, 1994; Gardner et al, 1994), was observed in
55% of the thyroid radiation-associated tumours (16/29). The
frequency of this SNP, which eliminates a BanI restriction site,
was similar in radiation-associated follicular adenomas and carci-
nomas (8/14 Ad: 57%, 6/11 PTC: 54.5%, and 2/4 WIFC: 50%;
Table 3). Among the adenomas, a higher frequency of SNP was
observed in microfollicular tumours (6/7: 86%), whereas the
frequency was similar in the follicular or papillary carcinomas
(Table 3). This 691 RET sequence variant was also detected in
20% of sporadic tumours (6/29) and 15% of the control normal
thyroid tissues (3/20) (Table 3). Again the highest frequency of
SNP among the sporadic tumours was observed in the microfolli-
cular adenomas (2/4: 50%).
With the aim of determining a relationship between C-cell
hyperplasia and the G691S RET SNP, we looked in the same thyr-
oid sample for the polymorphism in the tumoural tissue and for
the CCH in the surrounding peritumoural tissue. Our results
showed that ﬁrstly, the majority of the radiation-induced tumours
associated with a CCH (14/16: 88%), presented the polymorphism
and interestingly, in 75% of the cases (12/16) only the mutated
allele A2 was detected. Secondly, in the absence of CCH in peritu-
moural tissue only 14% (2/13) of the radiation-induced tumours
presented a 691 RET sequence variant in heterozygote form (A1/
A2) (Table 1 and Figure 2).
In the sporadic thyroid tumours, the C-cell hyperplasia was
observed in peritumoural tissue of only two of the 29 samples
(7%) which one of them presented only a mutated allele A2 (Table
2 and Figure 2). No G691S RET sequence variant was detected in
the DNA prepared from two of 20 samples of unrelated normal
thyroid tissues presenting a CCH. Three of the 18 samples remain-
ing were scored for the G691S RET SNP at heterozygote form (A1/
A2) (data not shown).
The blood samples were collected from 12 of our patients with
radiation-induced thyroid tumours, and the DNAs extracted from
the lymphocytes were screened for the G691S RET sequence
variant. Among them, seven samples were from patients with
tumours associated with a C-cell hyperplasia in peritumoural tissue
(Ti 226, 230, 233, 234, 239, 247 and 249 in Table 1). Six of them
were heterozygous (A1/A2) for the G691S SNP and interestingly, in
all of the cases the wild type allele A1 was lost in the tumours (loss
of heterozygosity?). The only exception was the case Ti 233 in
which the tumour as well as the lymphocytes showed only the
mutated allele A2. The DNA of lymphocytes of the other ﬁve
patients whose radiation-induced tumours were not associated with
a CCH presented as in the tumours, only a 691 codon wild type
sequence (Ti 101, 155, 225, 236 and 238 in Table 1). All the radia-
tion-associated tumours presenting a G691S RET SNP, with the
exception of samples Ti 233 and 255, were positive for a RET/
PTC1 or RET/PTC3 rearrangement. This was also the case for
the sporadic tumoural sample Ti 40 (Bounacer et al, 1997; Tables
1 and 2).
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Figure 1 (A) Presence of C-cell hyperplasia in the peritumoural tissue of
a radiation-induced thyroid tumour (T) of patient Ti226 (6100 magniﬁca-
tion). The arrows indicate calcitonin positive C-cells. (B) The same C-cell
hyperplasia seen with 6250 magniﬁcation. The calcitonin C-cells was de-
tected by immunohistochemistry using a polyclonal anti-calcitonin antibody.
Table 3 Frequency of G691S RET single nucleotide polymorphism in radiation-induced and sporadic thyroid
tumours
Radiation-induced thyroid tumours
16/29
b:55%
Sporadic thyroid tumours
6/29:20%
Normal thyroid tissue
3/20:15%
Adenomas
a
Mac. Ad. 1/4:25% 1/6:17% –
Mix. Ad. 1/3:33% 0/5:0% –
Mic. Ad. 6/7:86% 2/4:50% –
8/14:57% 3/15:20% –
WIFC 2/4:50% 0/2:0% –
PTC 6/11:54.5% 3/12:25% –
aMacr. Ad.=macrofollicular adenoma; Mix. Ad.=mixed adenoma (macro and microfollicular regions); Micr. Ad.=microfollicular
adenoma; PTC=papillary thyroid carcinoma; WIFC=widely invasive follicular carcinoma.
bNumber of positives/number of
tumours studied.
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British Journal of Cancer (2002) 86(12), 1929–1936 ã 2002 Cancer Research UKExamples of the RET G691S RET sequence variant studied by
sequence or restriction enzyme digestion, are given in Figure 3.
DISCUSSION
Our results show a signiﬁcantly higher frequency of C-cell hyper-
plasia in peritumoural thyroid tissues of radiation-induced
epithelial thyroid tumours (55%), than in peritumoural tissues of
sporadic thyroid tumours (7%) or in control normal thyroid
tissues (10%) (P=0.0001, Chi-square test). The presence of
CCH in the non-neoplastic tissue adjacent to follicular cell
tumours was previously reported with a frequency of 35% by
Albores-Saavedra et al (1988). However, the authors deﬁned
CCH when at least 50 C-cells were observed in only one lower
power ﬁeld (6100 magniﬁcation) rather than at least three ﬁelds
according to our criteria, and probably some of their positive cases
will be taken by us as a negative.
Several conditions such as hyperparathyroidism, hypercalcemia,
infancy and chronic lymphatic thyroiditis (Wolfe et al, 1975a,b;
Gibson et al, 1980; DeLellis, 1992; Tomita and Millard, 1992),
are now admittedly associated with CCH, whereas others, such as
age and sex, are still subject to controversy (Gibson et al, 1982;
O’Toole et al, 1985; Albores-Saavedra et al, 1988; Scopsi et al,
1991; Guyetant et al, 1997; Harach, 1997). In our patients with a
history of external radiation, no correlation has been seen in the
sex ratio between the CCH positive and CCH negative groups
(1.66 and 1.6 respectively). Moreover, we did not observe any
signiﬁcant difference (using Mann–Witney analysis) according to
age at diagnosis between these two groups (mean age: 26.6 years
in CCH positive group (excluding the youngest patients Ti85
and Ti233) and 37 years in CCH negative group). However, all
of the patients showing the CCH in normal tissue surrounding
tumours had received external radiation in infancy before the age
of 15 (with an average of 4.6 years) and their tumours occurred
with an average of 20 years. According to the fact that up to date
there is no data reporting that medullary thyroid carcinomas, in
which CCH is considered as a pre-neoplastic stage, are associated
with radiation, we can postulate an indirect role of irradiation in
the occurrence of CCH. In fact, we have shown the presence of
a sequence variant (GGT?AGT: gly?ser), in codon 691 of exon
11 of the RET gene, giving rise to a polymorphism, in 55% of
radiation-associated thyroid tumours. This polymorphism was
present in the majority (88%) of these radiation-induced tumours
associated with a CCH in peritumoural tissues. Interestingly, in
75% of these samples only the mutated allele A2 was detected.
In the absence of CCH, the polymorphism was observed in a
minority of the radiation-induced tumours in a heterozygous form
(A1/A2).
In sporadic epithelial thyroid tumours and in normal thyroid
tissues, the frequency of this polymorphism was similar (15 to
20%) and signiﬁcantly lower than in radiation-associated tumours
(P=0.0032, Chi-square test). Moreover, the C-cell hyperplasia was
observed in peritumoural tissue of only two of the 29 sporadic
thyroid tumours studied and just one of them presented a serine
residue (allele A2) on the codon 691 of the RET protein. In all
the other normal or tumoural sporadic thyroid tissues studied
for which the CCH was not observed, the sequence of the codon
691 RET was in wild type (majority of cases) or in heterozygote
form (A1/A2).
Our data indicate a correlation between the presence of a C-cell
hyperplasia in peritumoural irradiated thyroid tissue and the
presence of the mutated sequence in codon 691 of the RET protein
(allele A2) in neighbouring epithelial thyroid tumours. The mole-
cular bases of this relationship are actually unknown. The
possibility of the existence of some functional interconnections
between follicular and parafollicular C-cells, has been recently
evoked. For instance, Matias-Guiu (1999) and Volante et al
(1999) suggested that the microenvironment provided by MTC
cells may have the capacity to stimulate the proliferation of follicu-
lar cells, giving rise to hyperplastic and/or adenomatous follicles
which, sometimes, may evolve in these conditions to a fully
neoplastic phenotype. The opposite situation has also been
described: the presence of CCH in thyroid glands with Hashimoto’s
thyroiditis or adjacent to benign or malignant epithelial tumours
(Albores-Saavedra et al, 1988; Libbey et al, 1989; and our present
data). Furthermore, it has been also recently observed by Cosci
et al (2000) that the allele variants of RET G691S in exon 11 are
signiﬁcantly more frequent in patients with sporadic MTC than
in the general population. Moreover, it has been reported that a
neutral germline sequence variance S836S RET may somehow
predispose to sporadic MTC, especially those that harbour somatic
M918T mutation (Gimm et al, 1999). A highly signiﬁcant associa-
tion of RET polymorphisms, speciﬁcally the variant A45A, with
Hirschsprung disease has also been observed (Borrego et al, 1999,
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Figure 2 Frequency of radiation-induced (A) and sporadic (B) thyroid tumours (n=29) presenting a wild type allele A1, or mutated allele A2, or both
(A1+A2) in the presence or absence of C-cell hyperplasia in peritumoural tissue. C-cell hyperplasia was associated with 55% (16/29) of the tumours in (A)
and with only 7% (2/29) of the tumours in (B).
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data, we suggest that the higher frequency of CCH observed in the
irradiated thyroid glands of the patients bearing in their tumours a
G691S RET SNP, may be an effect of the RET allele (or haplotype)
on which the sequence variant has occurred.
The precise mechanism by which G691S affect the function of
RET protein is unknown and open to speculation. It has been
shown that polymorphic sequence variants can lead to production
of different amounts of mRNA (Leviev et al, 1997). It may be
suggested that the GGT?AGT polymorphism causes the creation
of a cryptic splice donor, splice acceptor or splice enhancer, there-
fore leading to an altered protein that may contribute to the
development of C-cell hyperplasia. Similar mechanisms have been
previously hypothesised in the cases of polymorphisms associated
with sporadic MTC and Hirschsprung disease (Borrego et al,
1999; Fitze et al, 1999; Gimm et al, 1999). Unfortunately, RNA
from our radio-induced thyroid tumours was not available to test
this hypothesis. It can be also postulated when an amino acid is
altered for example G691S, depending on the genotype, could
subtly alter the function of the RET protein if located in a critical
domain. If as a consequence of the radiation received by the thyr-
oid, a pre-existing heterozygous G691S SNP becomes homozygous,
the RET protein may be sufﬁciently affected to overcome a thresh-
old of activation and, alone or interacting with other molecules,
induce by still unknown mechanisms an accelerated growth of C-
cells (see below). This may explain the fact that the growth of
C-cells was not affected in 15% of our normal thyroid tissues
and 20% of the sporadic tumours, by the presence of an A1/A2
heterozygous form. This hypothesis may be supported by data
obtained studying the DNA of lymphocytes of some of our patients
who presented simultaneously, in their peritumoural thyroid
tissues a CCH, and in their radiation-associated tumours only
the mutated allele A2. Indeed, the majority of these lymphocytic
DNAs (6/7 samples) showed a heterozygous G691S RET variant
sequence (A1/A2), suggesting a probable loss of the wild type allele
A1 in the tumour samples. Unfortunately, lymphocytic material
was not available for all the studied cases; we can speculate a prob-
able similar situation for the cases in which the radiation-associated
tumours presented only the mutated allele A2 in association with a
CCH in peritumoural tissues.
Interestingly, all our radiation-induced thyroid tumours (except
Ti233 and Ti255) presenting the mutated allele A2 and showing a
CCH in peritumoural tissues are positive for RET/PTC rearrange-
ments (Table 1 and Bounacer et al, 1997). This association
between RET/PTC and the allele A2 may contribute to a CCH
observed in peritumoural tissues of these tumours. The hypothesis
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Figure 3 Example of G691 SNP in patient Ti226. (A) Direct sequence of exon 11 ampliﬁed DNA: (1) radiation-induced thyroid tumour showing mu-
tated allele A2; (2) lymphocytic DNA showing heterozygote form (A1+A2); (3) normal thyroid sample showing wild type allele A1. (B) BanI restriction
enzyme digestion of exon 11 ampliﬁed DNA: (1) non-digested; (2) radiation associated tumour (one band: allele A2); (3) lymphocytic DNA (three bands:
alleles A1+A2) and (4) normal thyroid sample (two bands: allele A1). In A and B the material studied after PCR is the same. In B M: marker Ø6174/HaeIII
digested DNA; 2% agarose gell stained with ethidium bromide. In A the arrow indicates the location of the transition G to A.
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lar cells may give rise to the development of a CCH in their
environment, can be supported by recent data from Bunone et al
(2000). Indeed these authors showed that there is RET expression
in thyroid benign or malignant tumoural follicular cells and in
these cells the RET promoter is always active after RET/PTC rear-
rangement. They reported also that a functional proto-RET
receptor might be expressed in epithelial thyroid carcinomas in
the absence of RET/PTC. Finally, the authors concluded that the
stimulation of RET expression may contribute to a simultaneous
or alternative higher proliferation of both follicular and neighbour-
ing parafollicular cells. In this context, we cannot exclude that the
mutated G691S RET allele, over-represented in the epithelial radia-
tion-associated tumours compared to controls, may lie in linkage
disequilibrium with other sequences that may confer low level
predisposition to or protection against anarchic growth of C-cells.
Furthermore, the possibilities of an interaction of the modiﬁed
RET protein with other molecules to stimulate C-cell growth must
not be neglected.
Theoretically, polymorphisms represent sequence variations,
which are present in the general population and confer no obvious
or important deleterious effects. However, it becomes clear that
some polymorphisms like the APC gene in colorectal cancer in
the Ashkenazim (Laken et al, 1997) and the paraoxonase gene in
coronary heart disease in type 2 diabetes (Ruiz et al, 1995) are
not entirely harmless. These observations taken together with our
present data argue in favour that RET G691S variant can constitute
a factor contributing to the development of CCH in the peri-
tumoural tissues of irradiated thyroid glands. Further efforts must
be aimed to conﬁrm a loss of the 691 RET wild type allele in the
irradiated thyroid tumours associated with a CCH; and also to
clarify by which mechanisms the microenvironment provided by
these tumours positive for G691S mutated allele has the capacity
to stimulate the development of CCH.
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